Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejectionand autoimmune and inflammatory diseases affecting the lungs, liver, kidney, eye, bone, and c...
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejectionand autoimmune and inflammatory diseases affecting the lungs, liver, kidney, eye, bone, and cartilage.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.